Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)

University Hospital, Bordeaux222 enrolled

Overview

Approximately 20% of patients diagnosed with Hodgkin lymphoma will eventually experience progression or relapse after first-line treatment, which carries a significant risk of disease-related death. Although several pilot studies have demonstrated high rates of sustained response with the combination of brentuximab vedotin (BV) and chemotherapy, consistent real-world data are still lacking. Moreover, there is no universally accepted salvage chemotherapy regimen in this setting, and clinical practices vary across centers. This study aims to describe the efficacy and toxicity of the BV + bendamustine (B2) regimen in patients with relapsed/refractory Hodgkin lymphoma (R/R HL) treated in France over a 10-year period, with or without an attempt at consolidative transplantation.

This study is a retrospective observational multicentric study. All patients fulfilling inclusion criteria in participant centers will be included. Clinical data will be obtained from patients medical records.

Study Type

OBSERVATIONAL

Enrollment

222

Conditions

Relapsed or Refractory Hodgkin Lymphoma

Interventions

Brentuximab-Vedotin associated with Bendamustine

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with relapsed or refractory HL, after at least one first line of treatment * Aged 18 years and over * Having received at least one course of the Brenxutimab-Vedotin J1 and Bendamustine J1 + J2 combination Exclusion Criteria: * Minor patients * Pregnant women

Locations (5)

CH de la Côte Basque, service Hématologie Clinique

Bayonne, France

CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire

Bordeaux, France

CHU de Caen, service Hématologie Clinique

Caen, France

Institut Paoli Calmettes, service Hématologie Clinique

Marseille, France

CHU de Toulouse, service Hématologie Clinique

Toulouse, France

Outcomes

Primary Outcomes

Progression free survival (PFS) for the whole cohort

Measured from the time of treatment initiation to the date of event : progression or death

Time frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

Secondary Outcomes

Overal survival (OS) for the whole cohort

Measured from the time of treatment initiation to the date of death

Time frame: From date of inclusion until the date of death from any cause assessed up to 120 months